IGC Pharma, Inc.
IGC$26M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaPOTOMAC70 employees
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 30, 2026
2dMarket Overview
Stock performance and key metrics
IGC News
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
IGC-AD1-Active Phase 2 Results Expected
Mar 30, 2026EstimatedIGC-AD1-Active164
Primary completion for IGC-AD1-Active trial (NCT05543681) in Alzheimer Disease
SourceDrug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IGC-AD1-Active | Phase 2 | Alzheimer Disease | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply